Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
March 16, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
BioMed X Launches New T Cell Immunology Discovery Platform
February 14, 2023 06:00 ET
|
BioMed X Institute (990552)
HEIDELBERG, Germany, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target...
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
January 30, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Explora BioLabs Launches Preclinical Vivarium Model in Seattle
January 24, 2022 11:00 ET
|
Explora BioLabs
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Explora BioLabs, the national provider of industry-leading preclinical vivarium research space and management services headquartered in San Diego, recently...
Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia
March 26, 2018 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical...
Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action
November 13, 2017 09:30 ET
|
Biothera Pharmaceuticals, Inc.
Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, Minn.,...
Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing
October 30, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy...
Biothera Announces Three Presentations at Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 27, 2017 11:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 27, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR)...